TAM
ZVRA icon

TFG Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

TFG Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,518
Closed -$1.72M – 40
2025
Q4 		$1.72M Buy
+192,518
New +$1.82M 0.36% 27

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

TFG Asset Management's ZVRA Position: Q1 2026 in Review

TFG Asset Management sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 192,518 shares — an estimated $1.72M sold.

TFG Asset Management first reported a position in ZVRA in Q4 2025 and held it in 1 quarter. The position peaked at $1.72M in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • TFG Asset Management reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TFG Asset Management sold 192,518 Zevra Therapeutics shares in Q1 2026, an estimated $1.72M.
  • TFG Asset Management first reported a position in Zevra Therapeutics in Q4 2025 and held it in 1 quarter.
  • TFG Asset Management's Zevra Therapeutics position peaked at $1.72M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on TFG Asset Management's 13F filing for Q1 2026, filed 15 May 2026.